EGFR and head and neck squamous cell carcinoma: Vandetanib, a multi-RTK inhibiting drug (targeting VEGFR-2, EGFR and RET), has been shown to reverse radioresistance both in vitro and in vivo in HNSCC, when given in combination with cisplatin [32].